8-K: Pacira BioSciences Reports Record 2023 Revenues and CFO Transition

Pacira BioSciences announced record full-year revenues of $675 million for 2023, alongside the departure of its CFO, Charles A. Reinhart, III, effective September 30, 2024.

Summary

• Pacira BioSciences reported record full-year revenues of $675 million for 2023, a 1% increase compared to 2022.
• The company's full-year GAAP net income was $42 million, or $0.91 per basic share, and adjusted EBITDA reached $214 million.
• Fourth-quarter revenues were $181.2 million, a 5% increase year-over-year, with a GAAP net income of $24.9 million.
• EXPAREL sales were $538.1 million for the full year, a slight increase from the previous year, while ZILRETTA sales grew by 5% to $111.1 million.
• iovera sales saw a significant 29% increase to $19.7 million for the full year.
• The company provided 2024 financial guidance, projecting total revenue between $680 million and $705 million, with a non-GAAP gross margin of 74% to 76%.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with record revenues and new product approvals, but the CFO departure and modest growth in some areas temper the overall sentiment. The company is well positioned for future growth.

Positives

• Pacira achieved record revenues for the full year 2023.
• The company saw significant growth in iovera sales.
• The FDA approved a new manufacturing suite for EXPAREL, which is expected to improve gross margins.
• EXPAREL's label expansion and new patents strengthen its market position.
• The company has a strong cash position of $281 million.
• Pacira is providing positive revenue guidance for 2024.

Negatives

• The company's CFO, Charles A. Reinhart, III, will be departing effective September 30, 2024.
• EXPAREL sales saw only a nominal increase for the full year 2023.
• Sales of bupivacaine liposome injectable suspension to third-party licensees decreased year-over-year.
• The company incurred significant operating expenses of $587.3 million for the full year 2023.

Risks

• The departure of the CFO could create uncertainty during the transition period.
• The company faces risks associated with integrating a new CEO.
• The company's future performance is subject to market acceptance of its products.
• The company's financial results are subject to various economic conditions, including inflation and rising interest rates.
• The company's success depends on the outcome of clinical trials and regulatory approvals.

Future Outlook

Pacira anticipates total revenue between $680 million and $705 million for 2024, with a non-GAAP gross margin of 74% to 76%. The company plans to advance the launch of EXPAREL in two key lower extremity nerve blocks and prepare for the NOPAIN catalyst.

Management Comments

• Frank D. Lee, chief executive officer of Pacira BioSciences, stated he is enthusiastic to lead the company and is focused on driving long-term growth, furthering a patient-centric culture, and establishing high standards for operational excellence.
• Management believes they have the people, the purpose, and the products to change the course of pain management and help save patients from opioid addiction.

Industry Context

Pacira operates in the non-opioid pain management and regenerative health solutions sector, which is experiencing growth due to increasing concerns about opioid addiction. The company's focus on long-acting local analgesics and drug-free pain control aligns with the industry's shift towards alternative pain management options.

Comparison to Industry Standards

• Pacira's revenue growth of 1% is modest compared to some high-growth biotech companies, but it is important to note that the company is already a large player in its niche.
• Companies like Heron Therapeutics (HRTX) also focus on non-opioid pain management, and their financial performance and product pipeline could be compared to Pacira's.
• Pacira's adjusted EBITDA of $214.5 million is a key metric that can be compared to other pharmaceutical and biotech companies of similar size.
• The company's focus on expanding the label for EXPAREL and securing new patents is a common strategy in the pharmaceutical industry to maintain a competitive edge.
• The approval of the new 200-liter manufacturing suite is a positive development that should improve Pacira's gross margins, which is a key metric for profitability.

Management Changes

Stakeholder Impact

• Shareholders will be impacted by the financial results and future guidance.
• Employees will be affected by the CFO transition and any restructuring efforts.
• Customers will benefit from the expanded availability of EXPAREL and other products.
• Suppliers will be impacted by the company's manufacturing and supply chain activities.
• Creditors will be interested in the company's financial health and ability to repay debt.

Next Steps

• Pacira plans to advance the launch of EXPAREL in two key lower extremity nerve blocks.
• The company will prepare for the significant catalyst ahead in NOPAIN.
• Pacira will reallocate efforts and resources to ensure the organization is best positioned for sustainable success.
• The company will start selling commercial product manufactured at the new 200-liter suite later this year.
• The company will conduct a search for a successor to the departing CFO.

Key Dates

Keywords

Pacira BioSciences, EXPAREL, ZILRETTA, iovera, Non-opioid pain management, Financial results, EBITDA, FDA approval, Nerve block, Patents, CFO departure